Breast Cancer

Top Story

ASCO expands enrollment for TAPUR study

ASCO expands enrollment for TAPUR study
November 17, 2017

ASCO announced four cohorts of Targeted Agent and Profiling Utilization Registry, or TAPUR, will enroll additional patients with a variety of cancers.

The combination of nivolumab (Opidvo, Bristol-Myers Squibb) plus ipilimumab (Yervoy, Bristol-Myers Squibb) also is being added to the study, bringing the number of drugs evaluated to 19, with 16 different targeted therapy options.

Meeting News

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

November 16, 2017
WASHINGTON — When diagnosed with Hodgkin lymphoma at…
FDA News

FDA authorizes IMPACT test to rapidly identify cancer mutations

November 15, 2017
The FDA today authorized Integrated Mutation Profiling of Actionable Cancer Targets, or IMPACT, an in vitro diagnostic test that uses next-generation sequencing to…
FDA News

FDA approves Faslodex in combination with Verzenio for advanced breast cancer

November 15, 2017
The FDA expanded the indication of fulvestrant to include its use with abemaciclib for treatment of certain women with advanced or metastatic breast cancer. The approval…
More Headlines »

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »

Baseball star who survived melanoma ‘suffering’ from lack of sunscreen use

September 22, 2017
More »
Resource Centers